Long-Term Use of Antihypertensive Agents and Risk of Breast Cancer: A Population-Based Case-Control Study

Overview

Journal Cardiol Ther

Specialty Cardiology & Vascular Diseases

Date 2015 Feb 7

PMID 25657096

Citations 11

Authors

Henry W C Leung

Li-Ling Hung

Agnes L F Chan

Chih-Hsin Mou

Affiliations

Soon will be listed here.

Abstract

Introduction: To evaluate the risk of breast cancer associated with long-term use of antihypertensive agents (AHs) in Taiwanese women with hypertension.

Methods: A search of the Taiwan National Health Insurance Research Database identified 330,699 patients with hypertension who were treated with antihypertensive drugs between January 1, 1998 and December 31, 2011. Logistic regression models were used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) between the use of AHs and breast cancer risk, adjusted for other types of antihypertensive drugs, statins and co-morbidities.

Results: Among the AHs used to treat the hypertensive women enrolled in our study, our analysis revealed that those treated with one specific particular class of beta-blockers (beta-1 selective beta-blockers) had an increased risk for breast cancer. We also found that the ever-use of calcium channel blockers (CCBs; i.e. for 13 years) was associated with breast cancer in an adjusted model (OR 1.09; 95% CI 1.03-1.16). However, the use of nonselective beta-blockers, selective and nonselective alpha-blockers, angiotensin-converting enzyme inhibitors and angiotensin II antagonists were not associated with breast cancer risk.

Conclusion: Based on the results of our analysis, long-term use of CCBs or beta-1 selective beta-blockers are likely to be associated with the risk of breast cancer. Further large comprehensive population-based studies to support our findings are required for confirmation of this conclusion.

Citing Articles

Epidemiology, risk factors and mechanism of breast cancer and atrial fibrillation.

Guo X, Zuo Z, Wang X, Sun Y, Xu D, Liu G Cardiooncology. 2024; 10(1):92.

PMID: 39716319 PMC: 11665102. DOI: 10.1186/s40959-024-00298-y.

Use of calcium channel blockers and risk of breast cancer among women aged 55 years and older: a nationwide population-based cohort study.

Lin S, Huang H, Chiang L, Huang L, Wang C Hypertens Res. 2023; 46(10):2272-2279.

PMID: 37253976 DOI: 10.1038/s41440-023-01321-y.

Association of Hypertension and Breast Cancer: Antihypertensive Drugs as an Effective Adjunctive in Breast Cancer Therapy.

Fan Y, Khan N, Khan M, Ahammad M, Zulfiqar T, Virk R Cancer Manag Res. 2022; 14:1323-1329.

PMID: 35392356 PMC: 8982807. DOI: 10.2147/CMAR.S350854.

Feeding in the first six months of life is associated with the probability of having bronchiolitis: a cohort study in Spain.

Gomez-Acebo I, Lechosa-Muniz C, Paz-Zulueta M, Sotos T, Alonso-Molero J, Llorca J Int Breastfeed J. 2021; 16(1):82.

PMID: 34663376 PMC: 8522099. DOI: 10.1186/s13006-021-00422-z.

The Effect of Local Renin Angiotensin System in the Common Types of Cancer.

Almutlaq M, Alamro A, Alamri H, Alghamdi A, Barhoumi T Front Endocrinol (Lausanne). 2021; 12:736361.

PMID: 34539580 PMC: 8446618. DOI: 10.3389/fendo.2021.736361.

References

Saltzman B, Weiss N, Sieh W, Fitzpatrick A, McTiernan A, Daling J . Use of antihypertensive medications and breast cancer risk. Cancer Causes Control. 2012; 24(2):365-71. DOI: 10.1007/s10552-012-0122-8. View

Bangalore S, Kumar S, Kjeldsen S, Makani H, Grossman E, Wetterslev J . Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2010; 12(1):65-82. DOI: 10.1016/S1470-2045(10)70260-6. View

Iseri O, Sahin F, Terzi Y, Yurtcu E, Erdem S, Sarialioglu F . beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration. Pharm Biol. 2014; 52(11):1374-81. DOI: 10.3109/13880209.2014.892513. View

Cakir Y, Plummer 3rd H, Tithof P, Schuller H . Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol. 2002; 21(1):153-7. View

Sloan E, Priceman S, Cox B, Yu S, Pimentel M, Tangkanangnukul V . The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010; 70(18):7042-52. PMC: 2940980. DOI: 10.1158/0008-5472.CAN-10-0522. View

Sipahi I, Debanne S, Rowland D, Simon D, Fang J . Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010; 11(7):627-36. PMC: 4070221. DOI: 10.1016/S1470-2045(10)70106-6. View

Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown E, Lee R, Meric-Bernstam F . Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011; 29(19):2645-52. PMC: 3139371. DOI: 10.1200/JCO.2010.33.4441. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Li C, Daling J, Tang M, Haugen K, Porter P, Malone K . Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med. 2013; 173(17):1629-37. PMC: 4112594. DOI: 10.1001/jamainternmed.2013.9071. View

10.

Lang K, Drell 4th T, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker K . Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer. 2004; 112(2):231-8. DOI: 10.1002/ijc.20410. View

11.

Madden K, Szpunar M, Brown E . β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell lines. Breast Cancer Res Treat. 2011; 130(3):747-58. PMC: 3126869. DOI: 10.1007/s10549-011-1348-y. View

12.

Pasternak B, Svanstrom H, Callreus T, Melbye M, Hviid A . Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011; 123(16):1729-36. DOI: 10.1161/CIRCULATIONAHA.110.007336. View

13.

Shah S, Carey I, Owen C, Harris T, DeWilde S, Cook D . Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol. 2011; 72(1):157-61. PMC: 3141198. DOI: 10.1111/j.1365-2125.2011.03980.x. View

14.

Powe D, Entschladen F . Targeted therapies: Using β-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol. 2011; 8(9):511-2. DOI: 10.1038/nrclinonc.2011.123. View

15.

Slotkin T, Zhang J, Dancel R, Garcia S, Willis C, Seidler F . Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat. 2000; 60(2):153-66. DOI: 10.1023/a:1006338232150. View

16.

Powe D, Voss M, Zanker K, Habashy H, Green A, Ellis I . Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2011; 1(7):628-638. PMC: 3248123. DOI: 10.18632/oncotarget.197. View

17.

Drell 4th T, Joseph J, Lang K, Niggemann B, Zaenker K, Entschladen F . Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat. 2003; 80(1):63-70. DOI: 10.1023/A:1024491219366. View

18.

Ganz P, Cole S . Expanding our therapeutic options: Beta blockers for breast cancer?. J Clin Oncol. 2011; 29(19):2612-6. DOI: 10.1200/JCO.2011.35.8820. View

19.

Ganz P, Habel L, Weltzien E, Caan B, Cole S . Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 2011; 129(2):549-56. PMC: 3145014. DOI: 10.1007/s10549-011-1505-3. View

20.

Carie A, Sebti S . A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene. 2007; 26(26):3777-88. DOI: 10.1038/sj.onc.1210172. View